Novartis Setback Raises Stakes in Multibillion-Dollar Drug Race
Summary
A setback for Novartis has intensified the race for Amgen and Eli Lilly to reduce heart attacks and strokes via Lp(a) lowering drugs.
Prepared by the newsroom with AI assistance; the original link is always provided
A recent setback for Novartis's cholesterol drug has cast uncertainty over a multibillion-dollar pharmaceutical market. The development reshapes the landscape for major drugmakers developing next-generation cardiovascular therapies.
The failure by Novartis significantly raises the stakes for key competitors, including Amgen and Eli Lilly. These pharmaceutical giants are racing to prove that lowering Lp(a) levels translates directly into fewer heart attacks and strokes.
Industry analysts and investors are now closely monitoring upcoming trial results from Amgen and Eli Lilly to assess the commercial and medical viability of this drug class.
Source: CNBC
Read the original →Latest news
Bank CenterCredit Repurchases Shares for 18.2B Tenge on KASE
Bank CenterCredit JSC has repurchased 4.1 million of its common shares on the Kazakhstan Stock Exchange for 18.2 billion tenge.
Source: KASE
Home Credit Bank Bonds Added to KASE T+ List
Starting October 8, Home Credit Bank bonds (KZQ000001213, HCBNe1) will be included in the KASE T+ List.
Source: KASE
KASE Publishes Member Activity Rankings for September 2026
Kazakhstan Stock Exchange has released its exchange member activity rankings for September 2026 on its official website.
Source: KASE
KASE Index rises 0.25% to 7,862.81 points
On October 7, the KASE Index climbed by 0.25% to settle at 7,862.81 points.
Source: KASE